Ashley Lynn
Nurse Practitioner · Normal, ILNPI 1205262508
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (28.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 41.0% of the total. 2025 is the largest year on record at $11,837, more than ten times the $36 reported in 2022. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $79.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- ADMA Biomanufacturing LLC$5K
- Sanofi$403
- Pharming Healthcare, Inc.$225
- GC Biopharma USA, Inc.$223
- Blueprint Medicines Corporation$204
- plus $2K from 25 others
What the payments were for
- Consulting fees$3,49225%
- Speaking & faculty fees$4,00028%
- Travel & lodging$2,56418%
- Food & beverage$3,93728%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $5,770 |
| ADMA Biomanufacturing LLC | 9 | $5,383 |
| Sanofi | 19 | $403 |
| Pharming Healthcare, Inc. | 12 | $225 |
| GC Biopharma USA, Inc. | 3 | $223 |
| Blueprint Medicines Corporation | 5 | $204 |
| Grifols USA, LLC | 10 | $193 |
| AstraZeneca | 10 | $189 |
| Octapharma USA, Inc. | 3 | $172 |
| Novartis | 6 | $162 |
| Genentech USA, Inc. | 4 | $146 |
| Incyte Corporation | 2 | $128 |
| Pfizer | 5 | $114 |
| Regeneron Healthcare Solutions, Inc. | 4 | $99 |
| GSK | 5 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $78 |
| Optinose US, Inc. | 4 | $77 |
| Ionis Pharmaceuticals, Inc. | 2 | $55 |
| Amgen | 2 | $43 |
| Phadia US Inc. | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 1 | $30 |
| AbbVie | 1 | $23 |
| Insmed, Inc. | 1 | $22 |
| Alk-abello, Inc | 1 | $22 |
| Itamar Medical Inc | 1 | $21 |
| Verona Pharma, Inc. | 1 | $19 |
| Bio Products Laboratory USA, Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Biocryst US Sales Co., LLC | 1 | $15 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,077 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nurse practitioner in Normal
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Erika VuckoChicago$76K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
- Dara McKinleyEvanston$66K
- Kristine WarnesNaperville$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.